Because of developments in healthcare systems and the availability of and need for advanced surgical procedures such as cardiovascular and transplant surgery, trauma treatment, and cancer and blood disease therapies, there is an increased need for donated blood. Every year, around 235 million major surgeries are performed worldwide, with 63 million being traumatic, over 31 million being cancer-related, and ten million being connected to pregnancy issues. In complex childbirths, blood transfusions are commonly administered to prepare for childhood congenital maternal blood abnormalities, acute anaemia, and trauma.
Newer technologies are widely utilised in high-income
countries and will be effectively adopted in middle and lower-income countries
in the coming decade, owing to an increase in blood donations, awareness about
blood safety, and healthcare expenditures around the world. Many developing
countries, such as India and China, rely on ELISA at the moment. The blood
screening market for NAT is now experiencing a significant slowdown in growth.
The exorbitant expense of modern testing has led to a higher usage of
first-generation ELISA assays, which are older and less efficient. Despite its
shortcomings, this exam is employed in many regions of the world. Geographically, North America is expected
to dominate the blood
screening market,
owing to acquisitions by major players in the region
The market is being driven by factors such as an
increase in blood donations and blood transfusion-related tests, an increase in
the frequency of infectious diseases, a growing elderly population, and more awareness
of transfusion-transmitted diseases. Untapped rising markets like India and
China, as well as technological advances, would provide significant growth
possibilities for this market throughout the projection period.